Free Trial
OTCMKTS:CRXM

Cardium Therapeutics (CRXM) Stock Price, News & Analysis

Cardium Therapeutics logo

About Cardium Therapeutics Stock (OTCMKTS:CRXM)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardium Therapeutics, Inc. was a biotechnology company focused on developing regenerative medicine products and therapies for tissue repair and cardiovascular applications. Its work included technologies designed to support wound healing and promote the growth of new blood vessels.

The company’s best-known product was Excellagen, a collagen-based topical gel developed for use in managing wounds. Cardium also advanced Generx, an investigational gene-therapy product intended to improve blood flow in patients with coronary artery disease, although the program remained developmental and did not become an approved commercial therapy.

Cardium’s activities were primarily centered on the United States. Publicly available information about its current operations, leadership, and active product portfolio is limited, and the company appears to have had little recent operating activity.

AI Generated. May Contain Errors.

Receive CRXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRXM Stock News Headlines

Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
See More Headlines

CRXM Stock Analysis - Frequently Asked Questions

Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardium Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO) and Intellipharmaceutics International (IPCIF).

Company Calendar

Today
10/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:CRXM
Previous Symbol
NYSE:CXM
CIK
772320
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (OTCMKTS:CRXM) was last updated on 10/5/2026 by MarketBeat.com Staff.
From Our Partners